This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Vortioxetine
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict WATCH-LIST MEDIUM
Cognitive enhancement claims (FOCUS DSST, CONNECT vs duloxetine) are real and replicated in MDD with cognitive symptoms — the strongest pro-cognitive signal of any modern antidepressant. But the validated indication is MDD with cognitive complaints, not "off-label nootropic for healthy 20-year-olds." For a 20yo MMA athlete + business owner with no MDD diagnosis, this is NOT a nootropic — the cognitive signal is the residual effect of treating depression-linked cognitive dysfunction, not a clean enhancement in healthy controls. Would consider STRONG-CANDIDATE only if (a) a future clinical episode of MDD develops where cognitive complaints dominate the presentation (DSST drop, executive dysfunction, "depressive pseudo-dementia" pattern), (b) cleaner SSRIs (escitalopram, sertraline) have been tried and either failed or caused unacceptable sexual dysfunction, and (c) prescriber agrees vortioxetine's cognitive-symptom data is the relevant tiebreaker. Sexual dysfunction profile is genuinely better than SSRIs (5-HT7 antagonism + reduced SERT-saturation), which matters for an athlete archetype, but again — not a reason to take it absent indication. Nausea (5-HT3 antagonism) is the dominant side effect; long half-life (~66 hours) is forgiving.
▸ Decision matrix by user profile Per-archetype
| Archetype | Verdict | Rationale |
|---|---|---|
★20-30, brain-priority, high cognitive workload, no MDD diagnosis (this-archetype — 20yo MMA + business owner) | WATCH-LIST | Not a nootropic in the Provigil/Adderall sense. The cognitive signal is in MDD with cognitive complaints — not a clean enhancement in healthy controls. Off-label use risks side effects (nausea, sexual dysfunction lower-than-SSRI but still present, weight, GI) without the documented upside. If a future MDD episode develops with prominent cognitive symptoms, this becomes a STRONG-CANDIDATE. |
30-50, executive maintenance, no MDD | S | logic. WATCH-LIST. |
50+, mild cognitive decline + mood symptoms | P | STRONG-CANDIDATE if MDD with cognitive complaints. The age cohort where FOCUS/CONNECT cognitive separation matters most. |
MDD with prominent cognitive symptoms (DSST-detectable processing-speed loss, executive dysfunction, "depressive pseudo-dementia") | STRONG-CANDIDATE | best evidence in this population. |
SSRI-induced sexual dysfunction (Jacobsen 2015 population) | STRONG-CANDIDATE | for switch. |
High athletic load, tested status | U | DEA, not WADA-prohibited as a class but always check current WADA list. Sexual dysfunction profile better than SSRIs is relevant for athlete archetype. |
Sleep-disordered | G | neutral on sleep — not a sleep tool. |
Recovery-focused / strength/anabolic | NOT-RELEVANT | — |
- ★20-30, brain-priority, high cognitive workload, no MDD diagnosis (this-archetype — 20yo MMA + business owner)WATCH-LIST
Not a nootropic in the Provigil/Adderall sense. The cognitive signal is in MDD with cognitive complaints — not a clean enhancement in healthy controls. Off-label use risks side effects (nausea, sexual dysfunction lower-than-SSRI but still present, weight, GI) without the documented upside. If a future MDD episode develops with prominent cognitive symptoms, this becomes a STRONG-CANDIDATE.
- 30-50, executive maintenance, no MDDS
logic. WATCH-LIST.
- 50+, mild cognitive decline + mood symptomsP
STRONG-CANDIDATE if MDD with cognitive complaints. The age cohort where FOCUS/CONNECT cognitive separation matters most.
- MDD with prominent cognitive symptoms (DSST-detectable processing-speed loss, executive dysfunction, "depressive pseudo-dementia")STRONG-CANDIDATE
best evidence in this population.
- SSRI-induced sexual dysfunction (Jacobsen 2015 population)STRONG-CANDIDATE
for switch.
- High athletic load, tested statusU
DEA, not WADA-prohibited as a class but always check current WADA list. Sexual dysfunction profile better than SSRIs is relevant for athlete archetype.
- Sleep-disorderedG
neutral on sleep — not a sleep tool.
- Recovery-focused / strength/anabolicNOT-RELEVANT
▸ Subjective experience (deep)
Week 1 nausea is the dominant complaint — usually self-limiting by week 2. Mood lift weeks 2-4 typical for SSRI/SNRI-class drugs. Cognitive effects (processing speed, less brain fog, easier to "find the word") often emerge alongside or slightly after the mood lift. Sexual side effects present but reportedly milder than SSRIs. Sleep usually neutral. Less emotional blunting than SSRIs anecdotally — possibly related to the 5-HT receptor modulation pattern vs pure SERT load.
▸ Tolerance + cycling deep dive
- Tolerance: not characteristic. Long-term efficacy maintained in extension studies up to 52 weeks.
- Not cycled — designed for steady-state daily use.
▸ Stacking deep dive
Avoid stacking with
- MAOIs (selegiline >10 mg, tranylcypromine, phenelzine, linezolid, methylene blue): contraindicated, 14-day washout each direction.
- Other SSRIs / SNRIs: redundant SERT load, serotonin syndrome risk in cross-titration.
- 5-HTP, L-tryptophan, St John's wort: serotonergic stack.
- Tramadol, meperidine, fentanyl, dextromethorphan high-dose: serotonergic opioids.
- Triptans (sumatriptan etc.): FDA class warning; clinical risk likely low but monitor.
- Strong CYP2D6 inhibitors: dose adjustment required (halve).
- Anticoagulants / chronic NSAIDs: modestly increased bleeding risk.
Compatible with
- Cognitive support stack (citicoline, alpha-GPC, omega-3 DHA, magnesium, creatine) — no PK conflicts; theoretical complementarity to vortioxetine's cortical effects, not formally studied.
- 5-HT3 antagonist anti-emetics (ondansetron, granisetron) — mechanistically redundant for nausea but PK-compatible. Has been used off-label for chemo nausea in vortioxetine-treated patients.
▸ Drug interactions deep dive
- CYP2D6 substrate (primary metabolism) — strong inhibitors (bupropion, fluoxetine, paroxetine, quinidine) approximately double exposure → halve dose.
- CYP3A4, 2A6, 2C9, 2C19, 2C8 minor pathways — strong inducers (rifampin, carbamazepine, phenytoin) reduce exposure.
- No clinically significant CYP inhibition by vortioxetine itself — unlike fluoxetine/paroxetine, doesn't drag down other meds.
- Lithium / digoxin: no significant PK interaction.
- Alcohol: no PK interaction shown but additive CNS effects possible; clinical caution.
▸ Pharmacogenomics
CYP2D6 phenotype matters. Poor metabolizers: ~2× exposure; FDA labeling recommends max 10 mg/day. Ultra-rapid metabolizers: under-exposure; may need 20 mg or alternative. CYP2D6 testing not required but can inform dosing for patients with hard-to-titrate response.
▸ Sourcing deep dive
| Path | Vendor | Cost | Reliability | Notes |
|---|---|---|---|---|
| Rx (US) | Pharmacy | $400-500/mo branded Trintellix; generics $30-100/mo since 2024-2025 | high | First US generics post-patent expiry. |
| Rx (EU/UK) | Pharmacy | varies | high | Brintellix/Trintellix branded; generics available in some markets. |
▸ Biomarkers to track (deep)
- Baseline: PHQ-9, MADRS or HAM-D if depression-tracking, DSST score (for the cognitive claim), sodium, LFTs, sexual function questionnaire (CSFQ-14 or ASEX), body weight, blood pressure.
- During use: PHQ-9 + DSST q4-6 weeks (the DSST tracker is the differentiator vs other antidepressants — track it specifically), sodium at 2 + 8 weeks, sexual function check, nausea log week 1-2, weight quarterly.
- Post-cycle: DSST + PHQ-9 reassessment to confirm cognitive + mood returns to baseline (or continues to improve, depending on trajectory).
▸ Controversies / open debates Live debate
- Pro-cognitive claim generalization: the FOCUS/CONNECT data are robust within MDD-with-cognitive-symptoms. Whether vortioxetine produces clean cognitive enhancement in healthy adults without MDD is unproven and the small healthy-volunteer literature does not robustly support it. Nootropic-community framing often skips this distinction.
- Mechanism contribution analysis: Sanchez 2015 review attributes the cognitive edge to 5-HT3 + 5-HT7 antagonism. Some pharmacologists argue the 5-HT7 antagonism is the dominant cognitive driver; others argue it's the cortical disinhibition from 5-HT3 antagonism. Both probably contribute; not yet possible to dissect cleanly.
- Brand-name confusion history: Originally launched as Brintellix (2013) — renamed to Trintellix in May 2016 by Lundbeck/Takeda after FDA-acknowledged confusion with Brilinta (ticagrelor, the antiplatelet drug). Same active ingredient, same labeling — only the name changed. Older literature uses Brintellix; newer uses Trintellix.
- Cipriani 2018 ranking: vortioxetine sat mid-to-upper tier in efficacy + acceptability, not top-tier. The cognitive endpoint differentiator is not what Cipriani 2018 measured (it used HAM-D/MADRS). Vortioxetine's case is "comparable mood efficacy + meaningfully better cognitive endpoint + meaningfully better sexual side effects" — so its real advantage is multidimensional, not visible in classical antidepressant rankings.
▸ Verdict change log
- 2026-05-10 — Initial verdict: WATCH-LIST. Cognitive enhancement claims real but indication-specific (MDD with cognitive symptoms); not validated as a healthy-adult nootropic.
▸ Open questions / gaps Open
- Does vortioxetine produce DSST gains in healthy adults without MDD? Small literature exists but not robust enough to recommend.
- Is the 5-HT7 antagonism or the 5-HT3 antagonism the dominant cognitive driver? Mechanistic dissection unfinished.
- Does the lower SERT-saturation profile (vs SSRIs) mean vortioxetine is less likely to produce emotional blunting? Anecdotal yes; formal trials lacking.
- Long-term (>2 yr) cognitive trajectory — does the DSST gain persist or plateau?
References
PMID 29477251
Cipriani 2018 network meta-analysis of 21 antidepressants.
View StudyPMID 24944261
McIntyre 2014 FOCUS trial; DSST primary endpoint in MDD with cognitive complaints.
View StudyPMID 27129428
McIntyre 2016 CONNECT trial; vortioxetine vs duloxetine head-to-head on cognition.
View StudyPMID 26257038
Mahableshwarkar 2015 duloxetine-referenced cognitive comparison.
View StudyPMID 26211700
Jacobsen 2015 vortioxetine vs escitalopram in SSRI-induced sexual dysfunction.
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.